SynthesisPloS one2014
Prognostic value of miR-21 in various cancers: an updating meta-analysis.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Diagnostic and Prognostic Accuracy of MiRNAs in Pancreatic Cancer: A Systematic Review and Meta-Analysis.Journal of cellular and molecular medicine · 2025Pooled it
- Pooled it
- Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients.Molecular diagnosis & therapy · 2018Pooled it
- MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis.Scientific reports · 2017Pooled it
- The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis.BioMed research international · 2017Pooled it
- MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis.Oncotarget · 2015Pooled it
- Prediction of poor prognosis in breast cancer patients based on microRNA-21 expression: a meta-analysis.PloS one · 2015Pooled it
- Neupogen/MSCs conditioned media inhibit HEp-2 laryngeal cancer cells proliferation by down regulating miRNA 21expression and ROS production.Molecular biology reports · 2026Article
- miRNAs in radiotherapy resistance of cancer; a comprehensive review.Cell biochemistry and biophysics · 2024Review
- Oncogenic Roles of UHRF1 in Cancer.Epigenomes · 2024Review
- Extracellular Vesicles from Cerebrospinal Fluid of Leptomeningeal Metastasis Patients Deliver MiR-21 and Induce Methotrexate Resistance in Lung Cancer Cells.International journal of molecular sciences · 2024Article
- MicroRNAs as Molecular Biomarkers for the Characterization of Basal-like Breast Tumor Subtype.Biomedicines · 2023Review
- Prognostic and diagnostic values of non-coding RNAs as biomarkers for breast cancer: An umbrella review and pan-cancer analysis.Frontiers in molecular biosciences · 2023Article
- microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells.International journal of molecular sciences · 2022Article
- Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients.American journal of cancer research · 2022Article
- Review
- Postoperative changes in plasma miR21-5p as a novel biomarker for colorectal cancer recurrence: A prospective study.Cancer science · 2021Article
- Three plasma-based microRNAs as potent diagnostic biomarkers for endometrial cancer.Cancer biomarkers : section A of Disease markers · 2021Article
- Tumor Tissue MIR92a and Plasma MIRs21 and 29a as Predictive Biomarkers Associated with Clinicopathological Features and Surgical Resection in a Prospective Study on Colorectal Cancer Patients.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, more and more studies investigated the value of microRNA (miRNA) as a diagnostic or prognostic biomarker in various cancers. MiR-21 was found dysregulated in almost all types of cancers. While the prognostic role of miR-21 in many cancers has been studied, the results were not consistent.
methodsWe performed a meta-analysis to investigate the correlation between miR-21 and survival of general cancers by calculating pooled hazard ratios (HR) and 95% confidence intervals (CI).
resultsThe pooled results of 63 published studies showed that elevated miR-21 was a predictor for poor survival of general carcinomas, with pooled HR of 1.91 (95%CI: 1.66-2.19) for OS, 1.42 (95% CI: 1.16-1.74) for DFS and 2.2 (95% CI: 1.64-2.96) for RFS/CSS. MiR-21 was also a prognostic biomarker in the patients who received adjuvant therapy, with pooled HR of 2.4 (95%CI: 1.18-4.9) for OS.
conclusionsOur results showed that miR-21 could act as a significant biomarker in the prognosis of various cancers. Further studies are warranted before the application of the useful biomarker in the clinical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.